Amorphous Drug Solubility via Pyrroplus Granulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Poorly water-soluble active ingredients, such as Atorvastatin, Leflunomide, Raloxifene, and Tadalafil, face challenges in oral solid dosage form development due to low solubility and bioavailability, leading to reduced therapeutic effects and increased variability, despite existing methods like particle size reduction and surfactant addition.
Innovation Solution
The 'Pyrroplus Manufacturing Process' employs 2-pyrrolidone as a dissolution enhancing agent combined with silicon dioxide, using a combination of wet and dry granulation to transform active ingredients from crystalline to amorphous states, enhancing solubility and bioavailability without affecting the dissolution profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional methods like particle size reduction and surfactant addition are used, then some solubility enhancement is achieved, but the bioavailability and dissolution rate remain insufficient for poorly water-soluble drugs
Solution Approach 1:
The patent transforms the crystalline active ingredient into an amorphous state through a specific manufacturing process involving melting and rapid cooling. This phase transition fundamentally changes the physical state and molecular arrangement of the drug, eliminating the ordered crystal lattice that hinders dissolution. The amorphous form exhibits superior solubility and dissolution rate compared to traditional crystalline forms, directly resolving the contradiction between solubility enhancement and bioavailability maintenance.
Solution Approach 2:
The invention creates a composite system by combining the amorphous active ingredient with specific excipients (hydrophilic polymers, surfactants, or lipids) during the granulation process. This composite approach leverages the synergistic effects between the amorphous drug and the excipient matrix, where the excipients further enhance solubility through mechanisms like solubilization, micelle formation, or amorphous solid dispersion, thereby achieving both improved solubility and reliable bioavailability.
2Stability of the object's composition
If the active ingredient is kept in crystalline form for stability, then storage stability is improved, but dissolution rate and bioavailability decrease
Solution Approach 1:
The patent applies a controlled phase transition from crystalline to amorphous state through a specific thermal process (melting followed by rapid cooling). This parameter change fundamentally alters the molecular arrangement, eliminating the stable but slow-dissolving crystal lattice. The resulting amorphous form maintains adequate stability through the granulation matrix while achieving rapid dissolution, thus resolving the contradiction between storage stability and dissolution rate.
Solution Approach 2:
The invention introduces hydrophilic polymers, surfactants, or lipids as intermediary substances that stabilize the amorphous active ingredient during storage. These intermediaries form a protective matrix around the amorphous drug molecules, preventing recrystallization and degradation while simultaneously enhancing dissolution by providing a hydrophilic environment. This mediator approach allows the amorphous form to achieve both stability and rapid dissolution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process significantly increases the solubility and bioavailability of poorly water-soluble active ingredients, achieving rapid dissolution and stable formulations with improved pharmacotechnical properties, overcoming the limitations of existing methods.
Implementation Method 1
using a combination of wet and dry granulation to transform active ingredients from crystalline to amorphous states, enhancing solubility and bioavailability
Implementation Method 2
The 'Pyrroplus Manufacturing Process' employs 2-pyrrolidone as a dissolution enhancing agent combined with silicon dioxide
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates to the implementation of a new method for manufacturing solid dosage forms for oral administration comprising poorly water soluble active ingredients which overcomes the associated solubility problems and affords improved dissolution profile.